ClinicalTrials.gg
CompletedNCT01922258Updated Nov 20, 2020Results posted

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

A Phase 3 interventional study of Brexpiprazole, OPC-34712 in Agitation Associated With, Alzheimer's Disease and Alzheimer's Type, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 71 sites in 9 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-11-20.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Otsuka Holdings Co., Ltd..

Enrollment
6th of 12
270 · median 265
Started
2013
with 1 other
Phase 3
13 of 17
none open now
Registered
9th of 17
by date

Among the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd., this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2013, is one of 13 in phase 3, and was the 9th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

To compare the efficacy of flexible dosing of brexpiprazole with placebo in subjects with agitation associated with dementia of the Alzheimer's type

Read the detailed description

Behavioral symptoms, such as agitation, are core features in subjects with Alzheimer's disease and related dementias and develop in the majority of dementia subjects. The presence of agitation in subjects with Alzheimer's disease places a significant burden not only on subjects and their caregivers but also on the healthcare system.

This is a trial designed to assess the safety and efficacy of flexible dosing of brexpiprazole in the treatment of subjects with agitation associated with dementia of the Alzheimer's type. The trial consists of a 12-week double-blind treatment period with a 30-day follow-up. The trial population will include male and female subjects between 55 and 90 years of age (inclusive) with a diagnosis of probable Alzheimer's disease, who are residing either in an institutionalized setting or in a non-institutionalized setting where the subject is not living alone.

03

Conditions studied

  • Agitation Associated With
  • Alzheimer's Disease
  • Alzheimer's Type
  • Mental Disorder
  • Nervous System Diseases

Keywords

  • OPC-34712
  • brexpiprazole
  • Dementia
  • Alzheimer's Disease
  • Cognitive Disorders
  • Agitation
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects 55 to 90 years of age, inclusive, at the time of .
  • Subjects who are residing at their current location for at least 14 days before screening and are expected to remain at the same location for the duration of the trial.
  • Subjects with diagnosis of probable Alzheimer's disease according to NINCDS-ADRDA criteria.
  • Subjects with a score of 5 to 22, inclusive, at screening and baseline visits.
  • Subjects with onset of symptoms of agitation at least 2 weeks prior to the screening visit.
  • Subjects with a total score greater than or equal to 4 on the agitation aggression item of the NPI-NH or NPI/NPI-NH at the screening and baseline visits.
  • Subjects who require pharmacotherapy for the treatment of agitation per the investigator's judgement, after an evaluation of reversible factors (eg, pain, infection, polypharmacy) and a trial of nonpharmacological interventions.
  • Subjects must have a previous MRI or CT scan of the brain, which was performed after the onset of symptoms of dementia, with findings consistent with the diagnosis of Alzheimer's disease.

Exclusion criteria

Exclusion Criteria:

  • Subjects with dementia or other memory impairment not due to Alzheimer's disease.
  • Subjects with history of stroke, well-documented , or pulmonary or cerebral embolism.
  • Subjects who currently have neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, gastrointestinal, or psychiatric disorders.
  • Subjects who have been diagnosed with an Axis I disorder ( criteria).
  • Subjects with uncontrolled hypertension.
  • Subjects with uncontrolled insulin-dependent diabetes mellitus (IDDM)
  • Subjects with epilepsy or a history of seizures.
  • Subjects considered in poor general health based on the investigator's judgment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
270 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching Placebo Once-Daily

    Drug: Brexpiprazole, OPC-34712

  • Experimental
    Brexpiprazole (flexible dose range 0.5 to 2 mg)

    Titrate up from 0.25 mg/day brexpiprazole to 1 mg/day brexpiprazole. After achieving 1 mg/day target dose may be increased or decreased based on efficacy and tolerability. Allowable flexible doses will be 0.5 mg/day, 1 mg/day, or 2 mg/day.

    Drug: Brexpiprazole, OPC-34712

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12/Early Termination in the Cohen-Mansfield Agitation Inventory (CMAI) Total Score

    The CMAI is widely used in clinical research for evaluation of agitation associated with Alzheimer's dementia, with reliability and validity in both institutionalized and noninstitutionalized participants. It consists of 29 items, all rated on a 1 to 7 scale (1=Never and 7=Several times in an hour), with 1 being the "best" rating and 7 being the "worst" rating. The total score is the sum of ratings for all 29 items. The possible total scores range from 29 to 203. The total score will be unevaluable if less than 24 of the 29 items are recorded. If 24 to 28 of the 29 items are recorded, the total score will be the mean of the recorded items multiplied by 29 and rounded to the first decimal place. The mean change from baseline (Day 0) to week 12 in the CMAI total score is reported. Statistical comparison of interest was brexpiprazole flexible dose versus placebo, analyzed using a mixed-effect model repeated measure approach. A decrease in score indicates improvement in symptoms.

    Time frame: From screening to week 12/early termination

Secondary outcomes

  1. Change in the Clinical Global Impression Severity of Illness (CGI-S) Score, as Related to Symptoms of Agitation

    The severity of agitation for each participant was rated using the CGI-S. The investigator (or designee) answered the following question: "Considering your total clinical experience with this particular population, how mentally ill (as related to agitation) was the participant at the observation period?" Response choices were 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. The score 0 (= not assessed) was set to missing. The CGI-S was therefore a 7-point scale (1-7). The primary analysis used a mixed-effect model repeated measure approach.

    Time frame: From screening to week 12/early termination

07

Results

Posted Jul 7, 2020

Participant flow

The trial was conducted at 62 sites in 9 countries: Bulgaria, Canada, Finland, France, Russia, Slovenia, Ukraine, the United Kingdom (UK), and the United States (US) and 270 participants were randomized. The date of the first ICF signed by a participant in this trial was 28 October 2013 and the date of the last trial observation was 30 March 2017.

Participant flow — Overall Study
MilestoneBrexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day)Placebo (Flexible Dose Range 0.5 to 2 mg/Day)
Started133137
Completed117121
Not completed1616
Withdrew: Lost to follow-up11
Withdrew: Adverse event92
Withdrew: Met withdrawal criteria04
Withdrew: Withdrawn by the investigator14
Withdrew: Withdrawal by participant55

Outcome measures

PrimaryChange From Baseline to Week 12/Early Termination in the Cohen-Mansfield Agitation Inventory (CMAI) Total Score

The CMAI is widely used in clinical research for evaluation of agitation associated with Alzheimer's dementia, with reliability and validity in both institutionalized and noninstitutionalized participants. It consists of 29 items, all rated on a 1 to 7 scale (1=Never and 7=Several times in an hour), with 1 being the "best" rating and 7 being the "worst" rating. The total score is the sum of ratings for all 29 items. The possible total scores range from 29 to 203. The total score will be unevaluable if less than 24 of the 29 items are recorded. If 24 to 28 of the 29 items are recorded, the total score will be the mean of the recorded items multiplied by 29 and rounded to the first decimal place. The mean change from baseline (Day 0) to week 12 in the CMAI total score is reported. Statistical comparison of interest was brexpiprazole flexible dose versus placebo, analyzed using a mixed-effect model repeated measure approach. A decrease in score indicates improvement in symptoms.

Time frame:
From screening to week 12/early termination
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12/Early Termination in the Cohen-Mansfield Agitation Inventory (CMAI) Total Score
units on a scaleBrexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day)Placebo (Flexible Dose Range 0.5 to 2 mg/Day)
Change From Baseline to Week 12/Early Termination in the Cohen-Mansfield Agitation Inventory (CMAI) Total Score-18.9 ± 1.17-16.5 ± 1.13
Statistical analysis
  • Brexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day) vs Placebo (Flexible Dose Range 0.5 to 2 mg/Day) · Mixed-effect model repeated measure · p = =0.1454 · Treatment difference: -2.34 · 95% CI -5.49 to 0.82
SecondaryChange in the Clinical Global Impression Severity of Illness (CGI-S) Score, as Related to Symptoms of Agitation

The severity of agitation for each participant was rated using the CGI-S. The investigator (or designee) answered the following question: "Considering your total clinical experience with this particular population, how mentally ill (as related to agitation) was the participant at the observation period?" Response choices were 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. The score 0 (= not assessed) was set to missing. The CGI-S was therefore a 7-point scale (1-7). The primary analysis used a mixed-effect model repeated measure approach.

Time frame:
From screening to week 12/early termination
Reported as:
Mean · units on a scale
Change in the Clinical Global Impression Severity of Illness (CGI-S) Score, as Related to Symptoms of Agitation
units on a scaleBrexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day)Placebo (Flexible Dose Range 0.5 to 2 mg/Day)
Change in the Clinical Global Impression Severity of Illness (CGI-S) Score, as Related to Symptoms of Agitation4.54 ± 0.774.51 ± 0.74

Adverse events

Collected over Through the trial: From screening to Week 12 and 30 (+2) days follow-up period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day)0/132 (0%)7/132 (5.3%)24/132 (18.2%)
Placebo (Flexible Dose Range 0.5 to 2 mg/Day)1/137 (0.7%)6/137 (4.4%)29/137 (21.2%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventBrexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day)Placebo (Flexible Dose Range 0.5 to 2 mg/Day)
SeizureNervous system disorders2/1320/137
Non-Cardiac Chest PainGeneral disorders1/1320/137
PneumoniaInfections and infestations1/1321/137
Subdural haematomaInjury, poisoning and procedural complications1/1320/137
Loss of consciousnessNervous system disorders1/1320/137
PresyncopeNervous system disorders1/1320/137
Dyspnoea ExertionalRespiratory, thoracic and mediastinal disorders1/1320/137
Hypertensive crisisVascular disorders1/1320/137
Gastrointestinal haemorrhageGastrointestinal disorders0/1321/137
Femur FractureInjury, poisoning and procedural complications0/1321/137
Most frequent other events
Most frequent other events
EventBrexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day)Placebo (Flexible Dose Range 0.5 to 2 mg/Day)
HeadacheNervous system disorders10/13217/137
SomnolenceNervous system disorders8/1325/137
DizzinessNervous system disorders6/1327/137

Baseline characteristics

All participants who were randomized into this trial. Participants were considered randomized when they were assigned a treatment number by interactive voice response system (IVRS) at the end of screening period. A participant who received trial treatment outside of the IVRS was not considered randomized, but safety was reported.

Age, Customized
Age, Customized(Participants)Brexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day)Placebo (Flexible Dose Range 0.5 to 2 mg/Day)Total
<65 years241943
>=65 <75 years464995
>=75 years6369132
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day)Placebo (Flexible Dose Range 0.5 to 2 mg/Day)Total
Female8288170
Male5149100
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day)Placebo (Flexible Dose Range 0.5 to 2 mg/Day)Total
American Indian or Alaska Native000
Asian033
Native Hawaiian or Other Pacific Islander000
Black or African American459
White128129257
More than one race000
Unknown or Not Reported101
08

Study locations

71 sites
  • Imperial, California 92251, United States
  • Lakewood, California 08755, United States
  • Long Beach, California 90806, United States
  • Long Beach, California 90822, United States
  • Panorama City, California 91402, United States
  • Universal City, California 91950, United States
  • Denver, Colorado 80209, United States
  • Bradenton, Florida 34205, United States
  • Miami, Florida 33142, United States
  • Miami, Florida 33165, United States
  • Miami, Florida 33176, United States
  • Orange City, Florida 32763, United States
  • Atlanta, Georgia 30331, United States
  • Smyrna, Georgia 30080, United States
  • Honolulu, Hawaii 96817, United States
  • Indianapolis, Indiana 46256, United States
  • Quincy, Massachusetts 02169, United States
  • South Dartmouth, Massachusetts 02747, United States
  • Ann Arbor, Michigan 48105, United States
  • Brooklyn, New York 11214, United States
  • Buffalo, New York 14215, United States
  • New Hyde Park, New York 11040, United States
  • Charlotte, North Carolina 28270, United States
  • Raleigh, North Carolina 27609, United States
  • Austin, Texas 78757, United States
  • Dallas, Texas 75231, United States
  • Dallas, Texas 75243, United States
  • Woodstock, Vermont 05091, United States
  • Burgas, 8000, Bulgaria
  • Kardzhali, 6600, Bulgaria
  • Pazardzhik, 4400, Bulgaria
  • Ruse, 7003, Bulgaria
  • Sofia, 1113, Bulgaria
  • Sofia, 1154, Bulgaria
  • Sofia, 1431, Bulgaria
  • Varna, 9020, Bulgaria
  • Veliko Tarnovo, 5000, Bulgaria
  • Penticton, British Columbia V2A 4M4, Canada
  • Kentville, B4N 4K9, Canada
  • Kuopio, 70210, Finland
  • Turku, 20520, Finland
  • Bourg en Bresse, 01012, France
  • Douai, 59500, France
  • Elancourt, 78990, France
  • Limoges, 87042, France
  • Nice, 06100, France
  • Toulouse, 31059, France
  • Tonnel'nyy, Stavropol Region 357034, Russian Federation
  • Ekaterinburg, 620030, Russian Federation
  • Saratov, 410060, Russian Federation
  • St. Petersburg, 188820, Russian Federation
  • St. Petersburg, 190005, Russian Federation
  • St. Petersburg, 195176, Russian Federation
  • St. Petersburg, 197341, Russian Federation
  • Ljubljana, 1000, Slovenia
  • Maribor, 2000, Slovenia
  • Sempeter pri Gorici, 5290, Slovenia
  • Donetsk, 83037, Ukraine
  • Kharkiv, 61068, Ukraine
  • Kharkov, 61068, Ukraine
  • Kherson, 73488, Ukraine
  • Kiev, 04080, Ukraine
  • Kiev, 04114, Ukraine
  • Lviv, 79021, Ukraine
  • Poltava, 36013, Ukraine
  • Simferopol, 95006, Ukraine
  • Vinnytsia, 21005, Ukraine
  • Crewe, CW1 2ER, United Kingdom
  • Manchester, M8 5RB, United Kingdom
  • Margate, CT20 1JY, United Kingdom
  • Torpoint, PL11 2TB, United Kingdom
09

References and documents

Publications

  • Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, Slomkowski M, Baker RA, McQuade RD, Cummings JL. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. Am J Geriatr Psychiatry. 2020 Apr;28(4):383-400. doi: 10.1016/j.jagp.2019.09.009. Epub 2019 Oct 1. PubMed 31708380 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Mar 2017, 42 months.

Results were first posted in Jul 2020, 3 years 4 months after primary completion. A results delay was requested in May 2018.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 42 months is close to that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2013
First posted
Aug 14, 2013
StartActual
Sep 2013
Primary completionActual
Mar 2017
CompletionActual
Mar 2017
Results delay requested
May 15, 2018
Results first posted
Jul 7, 2020
Last update
Nov 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01922258
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Aug 14, 2013
Start date
Sep 2013
Primary completion
Mar 2017
Completion
Mar 2017
Results posted
Jul 7, 2020
Last update
Nov 20, 2020

Study contacts

Eva Koheygi, MD
study director · Otsuka Pharmaceutical Development and Commercialization, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion